Skip to main content
S&P 5007,623.68-0.52%DOW52,215.16-1.23%NASDAQ25,955.34-0.21%BTC$80,645.00-0.98%ETH$2,373.55-0.82%GOLD$4,010.00-1.24%OIL$103.44+3.99%
Smart Investors Daily
SID Premium
AC

NASDAQ · ACON

Aclarion, Inc.

Healthcare · Medical - Healthcare Information Services

$1.93

Down-$0.01 (-0.26%)

Updated Oct 24, 2026, 3:54 PM

SID Score

3.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.59M
P/E ratio
-0.22
Dividend yield
0.00%
52-week range
$1.85 – $9.36
Volume
10.37K
Avg. volume
889.41K

Price performance · ACON

ACON price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 23, 2026

ACON closed at $1.93 after 21 trading sessions, down 25.48% for the selected period.

Last close
$1.93
Period change
-25.48%
Period low
$1.85
Period high
$2.59
Daily close
View OHLC price history
ACON OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 23, 2026$1.88$1.97$1.88$1.9310.37K
Oct 22, 2026$1.9386$1.9899$1.90$1.93515.05K
Oct 21, 2026$1.945$1.97$1.92$1.9510.45K
Oct 20, 2026$1.90$1.9999$1.882$1.9717.62K
Oct 19, 2026$1.8601$1.94$1.85$1.8913.85K
Oct 16, 2026$1.94$1.94$1.85$1.8511.6K
Oct 15, 2026$1.90$2.02$1.90$1.95327.24K
Oct 14, 2026$2.14$2.14$1.8901$1.9470.97K
Oct 13, 2026$2.25$2.25$2.0909$2.1421.36K
Oct 12, 2026$2.341$2.35$2.22$2.24526.98K
Oct 9, 2026$2.32$2.3653$2.32$2.347.3K
Oct 8, 2026$2.36$2.41$2.3001$2.3131.6K
Oct 7, 2026$2.32$2.39$2.32$2.3510.42K
Oct 6, 2026$2.3513$2.36$2.28$2.2930.91K
Oct 5, 2026$2.35$2.395$2.33$2.3433.18K
Oct 2, 2026$2.475$2.475$2.35$2.3815.75K
Oct 1, 2026$2.45$2.499$2.43$2.447.15K
Sep 30, 2026$2.44$2.46$2.40$2.4118.72K
Sep 29, 2026$2.48$2.60$2.32$2.3879.57K
Sep 28, 2026$2.645$2.7199$2.39$2.4475.47K
Sep 25, 2026$2.63$2.715$2.58$2.5930.14K

Latest ACON news

The latest Smart Investors Daily articles mentioning ACON.

Stock researchCompany · Overview

ACON research

Overview

Company profile and research snapshot.

Company profile

Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$23.46
Implied upside
—
Analysts
7
ACON recent ratings
DateFirmRatingTarget
May 29, 2026Ascendiant CapitalBuy—
Mar 25, 2026Ascendiant CapitalBuy—
Nov 20, 2025Ascendiant CapitalBuy—
Sep 19, 2025Ascendiant CapitalBuy—
Dec 13, 2024Maxim GroupHold—
Open full forecast

News briefing

Generated Oct 24, 2026, 3:01 PM

Why Is ACON Down Today?

Aclarion shares edged down 0.26% following the announcement of a new real-world publication validating its Nociscan® diagnostic technology. While the news itself is clinically positive, the modest decline suggests the market may have already priced in expectations for clinical validation, or investors are awaiting more concrete commercialization milestones.

    Bottom line: Aclarion's new publication validating Nociscan® represents clinical progress, but today's modest decline suggests investors want to see tangible commercialization metrics beyond peer-reviewed studies. Watch for upcoming announcements regarding reimbursement approvals, healthcare partnerships, or revenue guidance to gauge whether this technology gains real market traction.

    Yahoo · Oct 22, 2026

    Aclarion Announces New Real-World Publication: Nociscan® Validated by Strong Agreement with Discography in Diagnosing Painful Lumbar Discs

    Study conducted at London Spine Clinic found Nociscan's noninvasive scan successfully identified painful discs, agreeing with discography, the invasive gold standard, in up to 87% of casesNociscan also spared patients the needles, added cost, and recovery time that is often associated with discographyAuthors conclude Nociscan “may, in time, replace provocative lumbar discography” in appropriately selected patientsBolsters the case for physician adoption and payor support for Nociscan BROOMFIELD,

    Yahoo · Oct 20, 2026

    Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026

    85% year-over-year scan volume growth in Q3 2026, contributing to 117% growth for the nine months ended September 30, 2026European Spine Journal publishes peer-reviewed data supporting MRS as a potential viable alternative to provocative discographyCLARITY trial expanded to eleven clinical sites with updated enrollment criteria to accelerate recruitmentOverall CLARITY trial duration remains on track, with an update on enrollment progress and anticipated initial readout timing by year-end$14.2 mi

    Yahoo · Oct 13, 2026

    Aclarion to Present at the 20th Annual LD Micro Main Event

    BROOMFIELD, Colo., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Aclarion (NASDAQ: ACON) announced today that it will participate in the 20th Annual LD Micro Main Event, taking place October 19-21, 2026 at the Luxe Sunset Boulevard Hotel in Los Angeles, California. Aclarion is scheduled to present on Tuesday, October 20, 2026 at 11:30 AM PT. Brent Ness, Chief Executive Officer will represent the company. Presentation Details Event: LD Micro Main Event XXDate: Tuesday, October 20, 2026Time: 11:30 AMLocation:

    AI research layers

    Interpretive context generated from the platform’s current data sources.

    No results

    AI research layers have not been published yet.

    Featured By